1. A cross-sectional study on the potential drug-drug interaction risk of COVID-19 patients in hospital.
- Author
-
Huang LL, Jiang B, Han YL, and Liu Y
- Subjects
- Humans, Cross-Sectional Studies, Aged, Retrospective Studies, Male, Female, Risk Factors, Aged, 80 and over, Polypharmacy, Hospitalization statistics & numerical data, SARS-CoV-2, Incidence, Drug Interactions, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Drug Treatment
- Abstract
Objective: To investigate the incidence of and risk factors for potential drug-drug interactions (DDIs) among elderly patients with corona virus disease 2019 (-COVID-19) in hospital and to explore management strategies to reduce the occurrence of potential DDIs and ensure patient medication safety., Materials and Methods: This was a descriptive, retrospective cross-sectional study among patients aged 65 years and older who were hospitalized with COVID-19. Potential DDIs associated with prescriptions containing two or more medicines were analyzed with Lexicomp software, the incidence of DDIs was calculated, recommendations for medication adjustment were formulated, and the χ
2 -test and binary logistic regression were used to analyze related risk factors., Results: A total of 772 prescriptions were analyzed, 527 (68.26) of which involved 5,732 potential DDIs. The results of this study showed that a total of 152 (28.84%) prescriptions had 270 X risk class potential DDIs (i.e., avoid combining), 313 (59.39%) prescriptions had 1,161 D risk class potential DDIs (i.e., consider therapy modification), and 476 (90.32%) prescriptions had 4,301 C risk class potential DDIs (i.e., monitor therapy). The study findings showed that the total number of drugs (p < 0.001), the length of hospital stay (p < 0.001), and the number of comorbidities (p < 0.001) were risk factors affecting the occurrence of potential DDIs., Conclusion: This study identified factors associated with potential DDIs, which can assist in changing medication strategies, preventing adverse drug reactions, and improving clinical efficacy.- Published
- 2024
- Full Text
- View/download PDF